First Citizens Bank & Trust Co. Increases Stock Position in Becton, Dickinson and Company $BDX

First Citizens Bank & Trust Co. lifted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 5.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,270 shares of the medical instruments supplier’s stock after purchasing an additional 213 shares during the period. First Citizens Bank & Trust Co.’s holdings in Becton, Dickinson and Company were worth $736,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Brighton Jones LLC increased its position in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after buying an additional 877 shares in the last quarter. FORA Capital LLC acquired a new stake in shares of Becton, Dickinson and Company during the first quarter valued at $3,458,000. GAMMA Investing LLC increased its position in Becton, Dickinson and Company by 29.9% during the 1st quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier’s stock worth $744,000 after purchasing an additional 748 shares in the last quarter. Cacti Asset Management LLC raised its stake in Becton, Dickinson and Company by 0.8% in the 2nd quarter. Cacti Asset Management LLC now owns 180,271 shares of the medical instruments supplier’s stock valued at $30,801,000 after purchasing an additional 1,500 shares during the last quarter. Finally, Baker Tilly Wealth Management LLC lifted its holdings in Becton, Dickinson and Company by 25.4% in the 2nd quarter. Baker Tilly Wealth Management LLC now owns 6,898 shares of the medical instruments supplier’s stock valued at $1,188,000 after purchasing an additional 1,399 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Transactions at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director owned 22,226 shares in the company, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last three months, insiders have sold 1,838 shares of company stock worth $348,392. 0.36% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on BDX shares. Piper Sandler reissued a “neutral” rating and issued a $200.00 price objective (up previously from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Argus boosted their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Wall Street Zen upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Wells Fargo & Company lifted their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research report on Friday, August 8th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Friday. Three investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, Becton, Dickinson and Company presently has a consensus rating of “Hold” and an average price target of $205.40.

Becton, Dickinson and Company Trading Down 0.4%

BDX stock opened at $185.85 on Friday. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The company has a market cap of $53.27 billion, a price-to-earnings ratio of 33.43, a PEG ratio of 1.46 and a beta of 0.25. The business has a fifty day simple moving average of $189.93 and a 200-day simple moving average of $184.08. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. The firm had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%. On average, equities research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.